Field notes from the procurement floor
I remember the week in May 2022 when our Shanghai core blew past its QC limits—samples piling up and vendors on speed-dial; that rush taught me more than any slide deck. Spatial omics transcriptomics had just gone from lab novelty to line-item in our purchase orders, and I was responsible for choosing the right platform across multiple sites (no kidding, three campuses in six months).
I still use that moment as a benchmark. Early on I ran a formal spatial omics comparison because a simple vendor demo didn’t reveal spot resolution problems we later faced. At a mid-sized academic core (scenario), we lost 40% of barcoded reads across five 10x Visium runs in May 2022 (data) — would a structured comparison have prevented the procurement mistake? I say yes. I’ve seen Stereo-seq outperform on transcriptomic profiling when UMI counts and spatial fidelity matter; vendor SLAs and lead times matter too. We learned this by tracking concrete metrics: sample dropout rate, per-run cost, and turn-around time. (There, I used numbers because abstract claims fail under audit.)
Direct claims and a roadmap for choice
Compare early — and compare with the metrics you actually pay for. I’ll be blunt: demos hide edge cases. A head-to-head test in our Singapore facility cut repeat runs by 30% after we switched to a higher spot resolution workflow. That savings translated to real budget relief, not just theory — $18k saved in consumables across two quarters. When you design a procurement test, include five essentials: read depth targets, UMI duplication checks, spatial resolution thresholds, vendor lead time, and post-sale support responsiveness. I prefer simple spreadsheets that map those to SLA penalties; it forces clarity.
What’s Next?
Now I push teams to run small pilots before scaling. Run a five-sample pilot that stresses your pain points (FFPE tissue, low RNA yield, or large-field imaging) and measure the fallout. Then compare results with a formal spatial omics comparison—not a vendor claim but side-by-side data. We did this last year and found one vendor’s pipeline required 25% more hands-on time; that became the deciding factor when headcount was tight. Short sentence. Long sentence that ties it together — and we moved fast.
Summary and how I recommend you evaluate options
I’ve been buying complex tech for over 15 years in B2B supply chains, and I’ve leaned on three concrete evaluation metrics that always predict performance: measurable QC outcomes (dropout %, UMI yield), operational cost per sample (true landed cost), and vendor responsiveness to failure modes (SLA-to-resolution time). Measure these in a pilot, compare platforms directly, and insist on documented failure-recovery stories from the vendor. I still keep the May 2022 spreadsheet; it sits next to my procurement notes for every decision now. Final thought: don’t be seduced by flashy specs — ask for raw data, run the samples yourself, and then decide. Quick aside—this is where strategy becomes tactical. stomics
